Edge
StocktwitsEarnings

Official STOCKTWITS Representative

$BCRX Q2 '26 Earnings Results & Recap
• Reported GAAP EPS of $0.31 up 1450.00% YoY
• Reported revenue of $218.25M up 33.61% YoY
• BioCryst Pharmaceuticals maintained its full year 2026 ORLADEYO revenue guidance of $625 million to $645 million and increased its total revenue guidance to a range of $690 million to $715 million.Price since post
Advertisement|Remove ads.